Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology has launched an Expanded Access Program (EAP) for PB272 (neratinib) for U.S. patients with HER2-positive breast cancer or HER2-mutated cancers.

Puma Biotechnology, Inc.